Select Page

Cellular Intelligence strikes deal with Novo Nordisk to advance Parkinson’s cell therapy

by | May 11, 2026 | JPost | 0 comments

In this photo illustration, a smartphone displays the logo of Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company specializing in diabetes care, obesity treatment, in front of a screen showing the company
‘This cell therapy Parkinson’s program is truly innovative and exemplifies the powerful convergence of exciting academic discovery with the uncompromising quality of a global pharmaceutical leader.’

Subscribe to JPost Premium